TITLE: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Running title: CD20 mechanisms
نویسندگان
چکیده
word count: 194 Scientific Heading: Neoplasia Copyright (c) 2003 American Society of Hematology Blood First Edition Paper, prepublished online October 9, 2003; DOI 10.1182/blood-2003-06-2031 For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
منابع مشابه
Congenital JAK2V617F polycythemia vera: where does the genotype-phenotype diversity end?
1. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177:362-371. 2. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738-2743. 3. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by antiCD20 mAb correlates...
متن کاملAntibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.
Despite the success of anti-CD20 monoclonal antibody (mAb) in the treatment of lymphoma, there remains considerable uncertainty about their mechanism(s) of action. Here, we show that certain of these reagents (rituximab and 1F5), which redistribute CD20 into membrane rafts, are bound efficiently by C1q, deposit C3b, and result in complement-dependent cytotoxicity (CDC). This activity is importa...
متن کاملThe Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy
Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and autoimmune disease. However, the cellular and molecular pathways for B cell depletion remain undefined because human mechanistic studies are limited. Proposed mechanisms include antibody-, effector cell-, and complement-dependent cytotoxicity, the disruption of CD20 signaling pathways, and the induction of apoptosis....
متن کاملAssociation of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells
Non-Hodgkin lymphoma (NHL) is one of the most common hematologic malignancies among adults for which the chimeric monoclonal anti-CD20 antibody (Ab) rituximab (RTX) is used as first-line therapy. As RTX itself is not directly cytotoxic but relies on host immune effector mechanisms or chemotherapeutic agents to attack target cells, its therapeutic capacity may become limited when host effector m...
متن کاملMolecular mechanisms of the antitumor effects of anti-CD20 antibodies.
Anti-CD20 monoclonal antibodies (mAbs) have become the mainstay in the treatment of non-Hodgkin's lymphomas and have shown significant activity in patients with B-cell chronic lymphocytic leukemia. Antitumor action of these antibodies results from triggering of indirect effector mechanisms of the immune system that include activation of complement-dependent cytotoxicity (CDC), antibody-dependen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2003